文献速递胸部肿瘤

Datopotamab deruxtecan 在 EGFR 突变非小细胞肺癌患者中的汇总分析

A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.
PubMed 文献 · J Thorac Oncol · 2025-06-12

该探索性分析汇总了 TROPION-Lung05(II 期)和 TROPION-Lung01(III 期)两项试验的数据,评估 Datopotamab deruxtecan(Dato-DXd)在经靶向治疗和铂类化疗后进展的 EGFR 突变晚期或转移性非小细胞肺癌患者中的疗效与安全性。汇总 117 例患者,确认的客观缓解率为 43%(95%CI:34-52),中位无进展生存期 5.8 个月(95%CI:5.4-8.2),中位总生存期 15.6 个月(95%CI:13.1-19.0)。

要点

  • 汇总 117 例经多线治疗的 EGFR 突变晚期或转移性非小细胞肺癌患者,接受 Dato-DXd 6 mg/kg 每 3 周一次。
  • 确认的客观缓解率为 43%(95%CI:34-52),中位缓解持续时间 7.0 个月(95%CI:4.2-9.8)。
  • ≥3 级治疗相关不良事件发生率为 23%,严重不良事件发生率为 6%。

核心结论

  • Dato-DXd 在经 EGFR 靶向治疗和化疗后进展的 EGFR 突变晚期或转移性非小细胞肺癌患者中显示出有意义的临床活性,且安全性可接受。

研究设计与样本

  • 探索性汇总分析,数据来自 II 期 TROPION-Lung05(NCT04484142)和 III 期 TROPION-Lung01(NCT04656652)两项试验。
  • 汇总 117 例经靶向治疗和铂类化疗后的 EGFR 突变晚期或转移性非小细胞肺癌患者;TROPION-Lung05 中患者接受 Dato-DXd 6 mg/kg,TROPION-Lung01 中患者随机接受 Dato-DXd 6 mg/kg 或多西他赛 75 mg/m2,均每 3 周一次。
  • 终点包括经盲法独立中心审评的客观缓解率、缓解持续时间和无进展生存期,以及总生存期和安全性。

主要发现

  • 汇总人群经多线治疗(既往治疗中位三线;范围 1-5 线),以亚洲患者为主(69%)。
  • 最常见突变为外显子 19 缺失(51%)、L858R(32%)和 T790M(27%);可存在一个以上 EGFR 突变。
  • 确认的客观缓解率为 43%(95%CI:34-52),包括 5 例完全缓解(4%)。
  • 中位缓解持续时间为 7.0 个月(95%CI:4.2-9.8);中位无进展生存期 5.8 个月(95%CI:5.4-8.2);中位总生存期 15.6 个月(95%CI:13.1-19.0)。
  • Dato-DXd 的安全性特征与各项单独研究一致,未观察到新的安全性信号;≥3 级治疗相关不良事件发生率为 23%,严重不良事件发生率为 6%。

关键数值与推荐

  • Dato-DXd 给药方案为 6 mg/kg 每 3 周一次(TROPION-Lung05 及 TROPION-Lung01 中 Dato-DXd 组)。
  • 多西他赛给药方案为 75 mg/m2 每 3 周一次(TROPION-Lung01 中多西他赛组)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This exploratory analysis assessed datopotamab deruxtecan (Dato-DXd) in pretreated patients with advanced or metastatic NSCLC and EGFR mutations. METHODS: Data were pooled from the phase II TROPION-Lung05 (NCT04484142) and phase III TROPION-Lung01 (NCT04656652) trials. Patients with EGFR-mutated advanced or metastatic NSCLC, who had received previous targeted therapies and platinum-based chemotherapy, received Dato-DXd 6 mg/kg (TROPION-Lung05) or were randomized to Dato-DXd 6 mg/kg or docetaxel 75 mg/m2 (TROPION-Lung01) once every 3 weeks. End points included objective response rate, duration of response, and progression-free survival, all per blinded independent central review, overall survival, and safety. RESULTS: In total, 117 patients with EGFR mutations who received Dato-DXd were included in the pool. The population was heavily pretreated (median three lines of previous therapies; range, 1-5) and predominantly Asian (69%). The most common mutations were exon 19 deletion (51%), L858R (32%), and T790M (27%); more than one EGFR mutation could be present. The confirmed objective response rate was 43% (95% confidence interval [CI]: 34-52), including five complete responses (4%). Median duration of response was 7.0 months (95% CI: 4.2-9.8). Median progression-free survival and overall survival were 5.8 (95% CI: 5.4-8.2) and 15.6 months (95% CI: 13.1-19.0), respectively. The safety profile of Dato-DXd was consistent with the individual studies. No new safety signals were observed. Rates of grade greater than or equal to 3 treatment-related adverse events and serious adverse events were 23% and 6%, respectively. CONCLUSION: Dato-DXd demonstrated meaningful clinical activity in patients with EGFR-mutated advanced or metastatic NSCLC who had progressed on EGFR-directed therapies and chemotherapy, with an acceptable safety profile.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ahn MJ, Lisberg A, Goto Y, et al. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC. J Thorac Oncol. 2025. PMID: 40516821. doi:10.1016/j.jtho.2025.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。